-
STAT News – Biotech3 months agoSTAT+: Pharmalittle: We’re reading about Iran war’s impact on pharma supply chain, a Pfizer Lyme vaccine, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
STAT News – Biotech3 months agoSTAT+: Pfizer’s Lyme vaccine results set up tricky regulatory path
Pfizer and Valneva’s Lyme disease vaccine cut cases by about 73% in a Phase 3 trial, but missed its primary statistical endpoint — setting up a...
-
STAT News – Biotech3 months agoMatch Day results show impact of federal immigration policy
Salutations from San Diego. This is Jonathan Wosen, West Coast biotech & life sciences reporter. We’ve got an outstanding lineup for you today, featuring a look...
-
Uncategorized3 months agoEMA launches tools to accelerate development of medicines
The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an...
-
STAT News – Biotech3 months agoSTAT+: Doctronic raises $40 million as race to apply AI in clinical care heats up
Earlier this year the startup Doctronic launched a provocative, first-in-the-nation experiment to renew drug prescriptions with a chatbot. Now it’s refilling its coffers with $40 million...
-
Endpoints News3 months ago
Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss
Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2 maintenance...
-
Endpoints News3 months ago
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infection
Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting — possibly...
-
Uncategorized3 months agoCollaboration to advance precision oncology therapy
Oncology company One-carbon Therapeutics has entered a strategic collaboration with precision medicine company Tempus AI to advance precision oncology development. The collaboration will leverage Tempus’ proprietary,...
-
Endpoints News3 months ago
Sanofi extends $180M to California T cell engager startup Kali
Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup in...
-
STAT News – Biotech3 months agoSTAT+: Insmed drug benefits patients with rare, bacterial lung disease, study shows
Insmed said Monday that the addition of its drug Arikayce to a standard treatment for patients with a rare bacterial lung disease improved respiratory symptoms and...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
